Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The management of lomustine overdose in malignant glioma patients.

Literature DB >> 26034630

The management of lomustine overdose in malignant glioma patients.

Hans-Georg Wirsching¹, Isabel Tritschler¹, Antonella Palla¹, Christoph Renner¹, Michael Weller¹, Ghazaleh Tabatabai¹.

Abstract

Lomustine is an oral alkylating drug commonly used for brain tumor patients. Recently, the lomustine-containing PCV polychemotherapy regime (procarbazine, CCNU/lomustine, and vincristine) in combination with radiotherapy has become the standard of care for anaplastic oligodendroglioma with 1p/19q codeletion and high-risk low-grade glioma. Here, we review the literature of all reported cases of lomustine overdose, highlight complications by exemplifying a case of inadvertent lomustine overdose, and outline the management of this potential complication of outpatient PCV therapy.

Entities: Chemical Disease Species

Keywords: CCNU; PCV; glioma; lomustine; myelosuppression; overdose

Year: 2014 PMID： 26034630 PMCID： PMC4369719 DOI： 10.1093/nop/npu023

Source DB: PubMed Journal: Neurooncol Pract ISSN： 2054-2577

15 in total

1. CCNU overdose during PCV chemotherapy for anaplastic astrocytoma.

Authors: M Abele; M Leonhardt; J Dichgans; M Weller
Journal: J Neurol Date: 1998-04 Impact factor: 4.849

2. Inadvertent overdose with lomustine (CCNU) followed by hematologic recovery.

Authors: K A Foon; C M Haskell
Journal: Cancer Treat Rep Date: 1982-05

Review 3. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy.

Authors: Anat Gafter-Gvili; Abigail Fraser; Mical Paul; Liat Vidal; Theresa A Lawrie; Marianne D van de Wetering; Leontien C M Kremer; Leonard Leibovici
Journal: Cochrane Database Syst Rev Date: 2012-01-18

4. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.

Authors: Wolfgang Wick; Vinay K Puduvalli; Marc C Chamberlain; Martin J van den Bent; Antoine F Carpentier; Lawrence M Cher; Warren Mason; Michael Weller; Shengyan Hong; Luna Musib; Astra M Liepa; Donald E Thornton; Howard A Fine
Journal: J Clin Oncol Date: 2010-02-01 Impact factor: 44.544

5. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial.

Authors: Stefano Cascinu; Vincenzo Catalano; Luigi Cordella; Roberto Labianca; Paolo Giordani; Anna Maria Baldelli; Giordano D Beretta; Emilio Ubiali; Giuseppina Catalano
Journal: J Clin Oncol Date: 2002-08-15 Impact factor: 44.544

6. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Authors: Gregory Cairncross; Meihua Wang; Edward Shaw; Robert Jenkins; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperriere; Walter Curran; Minesh Mehta
Journal: J Clin Oncol Date: 2012-10-15 Impact factor: 44.544

7. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802.

Authors: Edward G Shaw; Meihua Wang; Stephen W Coons; David G Brachman; Jan C Buckner; Keith J Stelzer; Geoffrey R Barger; Paul D Brown; Mark R Gilbert; Minesh P Mehta
Journal: J Clin Oncol Date: 2012-07-30 Impact factor: 44.544

Review 8. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.

Authors: Nicole M Kuderer; David C Dale; Jeffrey Crawford; Gary H Lyman
Journal: J Clin Oncol Date: 2007-07-20 Impact factor: 44.544